Skip to main content

Dupilumab Dosage

Medically reviewed by Drugs.com. Last updated on Dec 15, 2020.

Applies to the following strengths: 100 mg/0.67 mL; 300 mg/2 mL; 200 mg/1.14 mL

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Atopic Dermatitis

600 mg subcutaneously once, then 300 mg subcutaneously every other week

Comments:
-A dose of 600 mg is administered as two 300 mg injections given at the same time at different sites.
-This drug can be used with or without topical corticosteroids.
-Topical calcineurin inhibitors may be used but should be reserved for problem areas only (e.g., face, neck, intertriginous, genital areas).

Use: For moderate-to-severe atopic dermatitis not adequately controlled with topical prescription therapies or when those therapies are not advisable

Usual Adult Dose for Asthma

For Patients with Asthma: 400 mg subcutaneously once, then 200 mg subcutaneously every other week OR 600 mg subcutaneously once, then 300 mg subcutaneously every other week

For Patients with Oral Corticosteroid-Dependent Asthma, Comorbid Moderate to Severe Atopic Dermatitis, or Comorbid CRSwNP: 600 mg subcutaneously once, then 300 mg subcutaneously every other week

Comments:
-A dose of 600 mg is administered as two 300 mg injections given at the same time at different sites; a dose of 400 mg is administered as two 200 mg injections given at the same time at different sites.
-This drug is not indicated for the relief of acute bronchospasm or status asthmaticus.

Use: As add-on maintenance treatment in patients with moderate-to-severe asthma with an eosinophilic phenotype or with oral corticosteroid dependent asthma.

Usual Adult Dose for Sinusitis

300 mg subcutaneously every other week

Use: As an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

Usual Pediatric Dose for Atopic Dermatitis

AGE: 6 years or older:
-Weight: 15 to less than 30 kg: 600 mg subcutaneously once, then 300 mg subcutaneously every 4 weeks
-Weight: 30 to less than 60 kg: 400 mg subcutaneously once, then 200 mg subcutaneously every other week
-Weight: 60 kg or greater: 600 mg subcutaneously once, then 300 mg subcutaneously every other week

Comments:
-A dose of 600 mg is administered as two 300 mg injections given at the same time at different sites; a dose of 400 mg is administered as two 200 mg injections given at the same time at different sites.
-This drug can be used with or without topical corticosteroids.
-Topical calcineurin inhibitors may be used but should be reserved for problem areas only (e.g., face, neck, intertriginous, genital areas).

Use: For patients 6 years and older with moderate-to-severe atopic dermatitis not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Usual Pediatric Dose for Asthma

For Patients 6 to 11 years old with Asthma:
-Weight: 15 to less than 30 kg: 100 mg subcutaneously every other week OR 300 mg subcutaneously every 4 weeks
-Weight: 30 kg or greater: 200 mg subcutaneously every other week

For Patients 6 to 11 years old with Oral Corticosteroid-Dependent Asthma or Comorbid Moderate to Severe Atopic Dermatitis:
-Weight: 15 to less than 30 kg: 600 mg subcutaneously once, then 300 mg subcutaneously every 4 weeks
-Weight: 30 to less than 60 kg: 400 mg subcutaneously once, then 200 mg subcutaneously every other week
-Weight: 60 kg or greater: 600 mg subcutaneously once, then 300 mg subcutaneously every other week

For Patients 12 years and older with Asthma: 400 mg subcutaneously once, then 200 mg subcutaneously every other week OR 600 mg subcutaneously once, then 300 mg subcutaneously every other week

For Patients 12 years and older with Oral Corticosteroid-Dependent Asthma, Comorbid Moderate to Severe Atopic Dermatitis, or Comorbid CRSwNP: 600 mg subcutaneously once, then 300 mg subcutaneously every other week

Comments:
-A dose of 600 mg is administered as two 300 mg injections given at the same time at different sites; a dose of 400 mg is administered as two 200 mg injections given at the same time at different sites.
-This drug is not indicated for the relief of acute bronchospasm or status asthmaticus.

Use: As add-on maintenance treatment in patients 6 years and older with moderate-to-severe asthma with an eosinophilic phenotype or with oral corticosteroid dependent asthma.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients

Safety and efficacy have not been established in patients younger than 6 years with atopic dermatitis or asthma, or in patients younger than 18 years with CRSwNP.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-For subcutaneous administration into the thigh or abdomen or upper arm
-Injection sites should be rotated; do not inject into skin that is tender, damaged, bruised or scarred
-Patients should receive proper training on preparation and administration prior to use; patients should be instructed to refer to Instructions for Use

MISSED Dose:
-If every other week dose is missed: Administer within 7 days from the missed dose and resume original schedule; if missed dose is not administered within 7 days, wait until next dose.
-If an every 4-week dose is missed: Administer within 7 days from missed dose and resume original schedule; if missed dose is not administered within 7 days, the patients should administer dose and start a new schedule based on this date

Storage requirements:
-Store refrigerated at 36F to 46F (2C to 8C); protect from light
-May be kept at room temperature up to 77F (25C) for a maximum of 14 days; do not expose to heat or direct sunlight
-Do not freeze; do not shake

Reconstitution/preparation techniques:
-Before injection, remove the prefilled syringe from the refrigerator and allow to reach room temperature (45 minutes for the 300 mg/2 mL prefilled syringe and 30 minutes for the 200 mg/1.14 mL prefilled syringe) without removing the needle cap
-Inspect visually for particulate matter and discoloration prior to administration; this drug should be a clear to slightly opalescent, colorless to pale yellow solution
-Do not use if the liquid contains visible particulate matter, is discolored or cloudy (other than clear to slightly opalescent, colorless to pale yellow)

General:
-This drug is not indicated for the relief of acute bronchospasm or status asthmaticus.

Patient advice:
-Patients should be instructed to read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
-Patients should be advised to seek medical advice if their asthma remains uncontrolled or worsens after starting treatment.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.